These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 26820260)

  • 1. High Prevalence and Incidence of HIV and HCV Among New Injecting Drug Users With a Large Proportion of Migrants--Is Prevention Failing?
    Folch C; Casabona J; Espelt A; Majó X; Meroño M; Gonzalez V; Wiessing L; Colom J; Brugal MT;
    Subst Use Misuse; 2016 Jan; 51(2):250-60. PubMed ID: 26820260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCV prevalence and risk behaviours among injectors of new psychoactive substances in a risk environment in Hungary-An expanding public health burden.
    Tarján A; Dudás M; Wiessing L; Horváth G; Rusvai E; Tresó B; Csohán Á
    Int J Drug Policy; 2017 Mar; 41():1-7. PubMed ID: 27984762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Undiagnosed HIV and Hepatitis C infection in people who inject drugs: From new evidence to better practice.
    Parés-Badell O; Espelt A; Folch C; Majó X; González V; Casabona J; Brugal MT
    J Subst Abuse Treat; 2017 Jun; 77():13-20. PubMed ID: 28476265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk behaviours and viral infections among drug injecting migrants from the former Soviet Union in Germany: Results from the DRUCK-study.
    Derks L; Gassowski M; Nielsen S; An der Heiden M; Bannert N; Bock CT; Bremer V; Kücherer C; Ross S; Wenz B; Marcus U; Zimmermann R;
    Int J Drug Policy; 2018 Sep; 59():54-62. PubMed ID: 30005420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
    Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R;
    BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High regional variability of HIV, HCV and injecting risks among people who inject drugs in Poland: comparing a cross-sectional bio-behavioural study with case-based surveillance.
    Rosińska M; Sierosławski J; Wiessing L
    BMC Infect Dis; 2015 Feb; 15():83. PubMed ID: 25879904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.
    Semá Baltazar C; Boothe M; Kellogg T; Ricardo P; Sathane I; Fazito E; Raymond HF; Temmerman M; Luchters S
    BMC Public Health; 2020 Jun; 20(1):851. PubMed ID: 32493347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
    Bird SM; Goldberg DJ; Hutchinson SJ
    J Epidemiol Biostat; 2001; 6(3):243-65; discussion 279-85. PubMed ID: 11437088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing Injecting Risk Behaviors of Long-Term Injectors with New Injectors in Tehran, Iran.
    Bazrafshan MR; Noroozi M; Ghisvand H; Noroozi A; Alibeigi N; Abbasi M; Higgs P; Armoon B
    Subst Use Misuse; 2019; 54(2):185-190. PubMed ID: 30474470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of HIV and other infections and injection behaviours among people who inject drugs in Addis Ababa, Ethiopia.
    Demissie M; Johnston LG; Muleta M; Desyebelew D; Belete W; G/Egxiabehre A; Gezahegn N; Kassa D; Aseffa Y
    Afr J AIDS Res; 2018 Sep; 17(3):259-264. PubMed ID: 30319040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
    Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
    Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for ending the HIV epidemic among persons who inject drugs in Haiphong, Vietnam.
    Des Jarlais DC; Thi Huong D; Thi Hai Oanh K; Khuê Pham M; Thi Giang H; Thi Tuyet Thanh N; Arasteh K; Feelemyer J; Hammett T; Peries M; Michel L; Vu Hai V; Roustide MJ; Moles JP; Laureillard D; Nagot N;
    Int J Drug Policy; 2016 Jun; 32():50-6. PubMed ID: 27006257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes.
    Vallejo F; Barrio G; Brugal MT; Pulido J; Toro C; Sordo L; Espelt A; Bravo MJ;
    J Epidemiol Community Health; 2015 Jun; 69(6):599-603. PubMed ID: 25870164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: need for large scale prevention programs.
    Uusküla A; Kals M; Rajaleid K; Abel K; Talu A; Rüütel K; Platt L; Rhodes T; Dehovitz J; Des Jarlais D
    J Public Health (Oxf); 2008 Jun; 30(2):119-25. PubMed ID: 18308743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys.
    Handanagic S; Bozicevic I; Civljak M; Dominkovic Z; Sevic S; Barbaric J; Nemeth Blazic T; Dakovic Rode O; Begovac J
    Int J Drug Policy; 2016 Jun; 32():57-63. PubMed ID: 27160504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevalence of human immunodeficiency virus and hepatitis C virus, and associated factors among injecting drug users in Catalonia].
    Huntington S; Folch C; González V; Meroño M; Ncube F; Casabona J
    Enferm Infecc Microbiol Clin; 2010 Apr; 28(4):236-8. PubMed ID: 19695744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys, 1992-2013.
    Hope VD; Harris R; McVeigh J; Cullen KJ; Smith J; Parry JV; DeAngelis D; Ncube F
    J Acquir Immune Defic Syndr; 2016 Mar; 71(3):331-7. PubMed ID: 26361173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV prevalence and gender differences among new injection-drug-users in Tallinn, Estonia: A persisting problem in a stable high prevalence epidemic.
    Uusküla A; Raag M; Marsh K; Talu A; Vorobjov S; Des Jarlais D
    PLoS One; 2017; 12(2):e0170956. PubMed ID: 28152026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance and image enhancing drug injectors' access to needle syringe programs: Responding to a public policy dilemma.
    van Beek I; Chronister KJ
    Int J Drug Policy; 2015 Sep; 26(9):868-74. PubMed ID: 26118797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of markers for hepatitis B virus and HIV-1 among drug injectors in London: injecting careers, positivity and risk behaviour.
    Rhodes T; Hunter GM; Stimson GV; Donoghoe MC; Noble A; Parry J; Chalmers C
    Addiction; 1996 Oct; 91(10):1457-67. PubMed ID: 8917914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.